

ASX ANNOUNCEMENT

Anti-viral Activity


- Anti-viral activity against Influenza
- Concentrations of RECCE® 327 well within therapeutic windows

Sydney, New South Wales, 13 July 2016 – Recce Ltd (ASX: RCE) the developer of a new class of patented drugs targeted at antibiotic and anti-cancer human applications, is pleased to announce that anti-viral activity was evident during *in-vitro* tests of RECCE® 327 against Influenza, by an independent Contract Research Organisation in USA.

The results are presented below.

1. RECCE® 327 vs Influenza, outside of VERO (Monkey) cells

The graph and table below, present the data derived from the test, an industry standard Plaque-Reduction Neutralization Test Assay (PRNT). In this test, within separate well-plates, the dose of RECCE® 327 was sequentially doubled, to assess the compound's activity against Influenza A (IFV A) virus strain TX/36/91 (H1N1); activity was represented by % inhibition of the virus's activity on the monkey cells:



RECCE® 327%	0.000195	0.000391	0.000781	0.001563	0.003125	0.00625	0.0125	0.025	0.05	0.1
% Inhibition	0.0	13.2	7.7	8.2	31.1	56.3	68.6	88.9	99.4	100.0
SD	0.0	13.1	7.0	11.5	12.2	9.6	14.8	0.0	0.9	0.0

The data suggest:

- RECCE® 327 may be used to target viruses located external to cells - common when the invading virus is located between a parent cell and a new host-cell – and thus preventing the virus from spreading



ASX: RCE

Head Office - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899


Sydney Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (2) 8075 4707

Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

- b) There was a direct, linear relationship between concentration of RECCE® 327, and inhibition of the virus
- c) That the inhibition/kill (the distinction between the terms is somewhat pedantic, and varies among observers) resulting in effect upon monkey cells was anti-viral, and not due to toxicity, was demonstrated as dose-dependent inhibition of the influenza virus was observed outside of the range of any toxicity to the VERO (monkey) cells.

2. RECCE® 327 vs Influenza inside MDCK (Dog) cells

The graph and table below, present the data derived from an industry standard Cytopathic Effect Assay (CPE). In this test, within separate well-plates, the dose of RECCE® 327 was sequentially doubled, to assess the compound's activity against Influenza A (IFV A) virus strain TX/36/91 (H1N1) within MDCK cells; activity was represented by % inhibition of the virus's activity within the MDCK (dog) cells:



RECCE® 327%	0.003125	0.00625	0.0125	0.025	0.05	0.1
% Inhibition	42.2	47.5	51.2	45.1	57.9	62.2
SD	2.0	6.9	1.1	7.9	10.5	8.9

The data suggest:

- a) RECCE® 327 may be used to target viruses located within cells, the common location of invading viruses – and preventing the virus from spreading
- b) Even at a very low concentration (0.003125%), RECCE® 327 inhibited/killed 42% of the virus, even when 'hidden' within the cell
- c) There was a direct, linear relationship between concentration of RECCE® 327, and inhibition of the virus. Low concentration (0.1%) of RECCE® 327 showed 62% of the virus had been inhibited/killed – well within the therapeutic dosing window
- d) A trend towards 100% inhibition/kill rate was observed and if the test was continued, may see this achieved even when the virus is hidden within a cell – the home for most viruses
- e) RECCE® 327 did not exhibit any toxicity to the MDCK (Dog) cells.

Recce has lodged a patent application to include the above data in the aim of securing this potentially significant opportunity for Recce. The next step will be to continue the preliminary assessment of Recce's anti-viral capabilities through a projected *in-vivo* test, outlined in Recce's last announcement.



If successful, Recce would take the opportunity of drawing the FDA's attention to this, as well as Recce's additional capabilities against cancers and/or bacteria – a very rare total capability.

Dr Graham Melrose, Executive Chairman commented “This is an early, but very encouraging development - RECCE® 327 may be the first drug in history to be purposefully targeted against bacteria, viruses and cancer”.

For further information please visit www.recce.com.au or contact:

Investor Relations

Peter Williams
CFO & Company Secretary
Recce Ltd
Tel: +61 8 9253 9800

Media Communication

Karen Oswald - karen.oswald@markocommunications.com.au
Gary Buchholz – gary@markocommunications.com.au
Marko Communications
Tel: +61 423 602 353

About Recce Ltd

Recce Ltd (ASX: RCE) is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method.

RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use.

Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327.

The discovery of RECCE® 327's capabilities against cancer (as well as bacteria-superbugs) has greatly increased the value of the Company's technology, especially in view of synergism between the anti-cancer and antibiotic properties.

Recce has granted patents in Australia, United States, Europe, Japan and China – giving it legal monopolies and potential financial returns from manufacture and distribution in about 80% of the world's pharmaceutical markets.

To receive the latest information on Recce - [Subscribe here](#)

